These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

435 related items for PubMed ID: 26767422

  • 1. Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts.
    Lambiase PD, Gold MR, Hood M, Boersma L, Theuns DAMJ, Burke MC, Weiss R, Russo AM, Kääb S, Knight BP.
    Heart Rhythm; 2016 May; 13(5):1066-1074. PubMed ID: 26767422
    [Abstract] [Full Text] [Related]

  • 2. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
    Weinstock J, Bader YH, Maron MS, Rowin EJ, Link MS.
    J Am Heart Assoc; 2016 Feb 12; 5(2):. PubMed ID: 26873684
    [Abstract] [Full Text] [Related]

  • 3. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
    Nazer B, Dale Z, Carrassa G, Reza N, Ustunkaya T, Papoutsidakis N, Gray A, Howell SJ, Elman MR, Pieragnoli P, Ricciardi G, Jacoby D, Frankel DS, Owens A, Olivotto I, Heitner SB.
    Heart Rhythm; 2020 Jul 12; 17(7):1107-1114. PubMed ID: 32084597
    [Abstract] [Full Text] [Related]

  • 4. Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy.
    Maurizi N, Olivotto I, Olde Nordkamp LR, Baldini K, Fumagalli C, Brouwer TF, Knops RE, Cecchi F.
    Heart Rhythm; 2016 Feb 12; 13(2):457-63. PubMed ID: 26362577
    [Abstract] [Full Text] [Related]

  • 5. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
    Syska P, Przybylski A, Chojnowska L, Lewandowski M, Sterliński M, Maciag A, Gepner K, Pytkowski M, Kowalik I, Maczyńska-Mazuruk R, Ruzyłło W, Szwed H.
    J Cardiovasc Electrophysiol; 2010 Aug 01; 21(8):883-9. PubMed ID: 20132378
    [Abstract] [Full Text] [Related]

  • 6. Inappropriate shocks in the subcutaneous ICD: Incidence, predictors and management.
    Olde Nordkamp LR, Brouwer TF, Barr C, Theuns DA, Boersma LV, Johansen JB, Neuzil P, Wilde AA, Carter N, Husby M, Lambiase PD, Knops RE.
    Int J Cardiol; 2015 Sep 15; 195():126-33. PubMed ID: 26026928
    [Abstract] [Full Text] [Related]

  • 7. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties.
    Przybylski A, Małecka L, Pytkowski M, Chojnowska L, Lewandowski M, Sterliński M, Maciag A, Ruzyłło W, Szwed H.
    Kardiol Pol; 2005 Oct 15; 63(4):391-7; discussion 398. PubMed ID: 16273479
    [Abstract] [Full Text] [Related]

  • 8. Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.
    Yazaki K, Suzuki A, Shiga T, Minami Y, Arai K, Ashihara K, Shoda M, Hagiwara N.
    BMC Cardiovasc Disord; 2021 Feb 19; 21(1):106. PubMed ID: 33607967
    [Abstract] [Full Text] [Related]

  • 9. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NA, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P.
    JAMA; 2007 Jul 25; 298(4):405-12. PubMed ID: 17652294
    [Abstract] [Full Text] [Related]

  • 10. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
    Weissler-Snir A, Dorian P, Rakowski H, Care M, Spears D.
    Heart Rhythm; 2021 Jan 25; 18(1):63-70. PubMed ID: 32800967
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness of subcutaneous implantable cardioverter-defibrillator testing in patients with hypertrophic cardiomyopathy.
    Maurizi N, Tanini I, Olivotto I, Amendola E, Limongelli G, Losi MA, Allocca G, Perego GB, Pieragnoli P, Ricciardi G, De Filippo P, Ferrari P, Quarta G, Viani S, Rapacciuolo A, Bongiorni MG, Cecchi F.
    Int J Cardiol; 2017 Mar 15; 231():115-119. PubMed ID: 28073660
    [Abstract] [Full Text] [Related]

  • 12. Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy.
    Maron BJ, Maron MS.
    Heart Rhythm; 2016 May 15; 13(5):1155-1165. PubMed ID: 26749314
    [Abstract] [Full Text] [Related]

  • 13. Appropriate Implantable Defibrillator Therapy in Adults With Hypertrophic Cardiomyopathy.
    Thavikulwat AC, Tomson TT, Knight BP, Bonow RO, Choudhury L.
    J Cardiovasc Electrophysiol; 2016 Aug 15; 27(8):953-60. PubMed ID: 27138377
    [Abstract] [Full Text] [Related]

  • 14. Low Prevalence of Inappropriate Shocks in Patients With Inherited Arrhythmia Syndromes With the Subcutaneous Implantable Defibrillator Single Center Experience and Long-Term Follow-Up.
    Rudic B, Tülümen E, Berlin V, Röger S, Stach K, Liebe V, El-Battrawy I, Dösch C, Papavassiliu T, Akin I, Borggrefe M, Kuschyk J.
    J Am Heart Assoc; 2017 Oct 17; 6(10):. PubMed ID: 29042423
    [Abstract] [Full Text] [Related]

  • 15. Prognostic Implications of Defibrillation Threshold Testing in Patients With Hypertrophic Cardiomyopathy.
    Francia P, Adduci C, Semprini L, Palano F, Santini D, Musumeci B, Santolamazza C, Volpe M, Autore C.
    J Cardiovasc Electrophysiol; 2017 Jan 17; 28(1):103-108. PubMed ID: 27862589
    [Abstract] [Full Text] [Related]

  • 16. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
    Maron BJ, Casey SA, Olivotto I, Sherrid MV, Semsarian C, Autore C, Ahmed A, Boriani G, Francia P, Winters SL, Giudici M, Koulova A, Garberich R, Rowin EJ, Sears SF, Maron MS, Spirito P.
    Circ Arrhythm Electrophysiol; 2018 Apr 17; 11(4):e005820. PubMed ID: 29625970
    [Abstract] [Full Text] [Related]

  • 17. Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy.
    Francia P, Adduci C, Palano F, Semprini L, Serdoz A, Montesanti D, Santini D, Musumeci B, Salvati A, Volpe M, Autore C.
    J Cardiovasc Electrophysiol; 2015 Aug 17; 26(8):893-899. PubMed ID: 25996259
    [Abstract] [Full Text] [Related]

  • 18. Long-Term Outcome in High-Risk Patients With Hypertrophic Cardiomyopathy After Primary Prevention Defibrillator Implants.
    Rowin EJ, Burrows A, Madias C, Estes NAM, Link MS, Maron MS, Maron BJ.
    Circ Arrhythm Electrophysiol; 2020 Oct 17; 13(10):e008123. PubMed ID: 32897759
    [Abstract] [Full Text] [Related]

  • 19. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.
    Alsheikh-Ali AA, Link MS, Semsarian C, Shen WK, Estes NA, Maron MS, Haas TS, Formisano F, Boriani G, Spirito P, Maron BJ.
    Heart Rhythm; 2013 Feb 17; 10(2):214-8. PubMed ID: 23041573
    [Abstract] [Full Text] [Related]

  • 20. Performance of the subcutaneous implantable cardioverter-defibrillator in patients with a primary prevention indication with and without a reduced ejection fraction versus patients with a secondary prevention indication.
    Boersma LV, Barr CS, Burke MC, Leon AR, Theuns DA, Herre JM, Weiss R, Kremers MS, Neuzil P, Husby MP, Carter N, Stivland TM, Gold MR, EFFORTLESS and IDE Study Investigators.
    Heart Rhythm; 2017 Mar 17; 14(3):367-375. PubMed ID: 27890798
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.